Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 9/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stevioside SCHEMBL18122116 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL13401728 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL14633820 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL24450708 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL22922182 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL23228765 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL21977148 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL21266958 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL20878260 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 | |
| Stevioside SCHEMBL1822342 | 1.00 | SELP (0.53) | SELPATMPTPN1F3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271155-A1 | Vitamin Formulations | NESTEC SA (CH) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271155-A1 | Vitamin Formulations | CYP24A1, VDR, CYP2R1 | SELP 934/4885ATM 4882/4885PTPN1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.